Dataset Information


Treatment of metastatic colorectal cancer: focus on panitumumab.

ABSTRACT: Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.


PROVIDER: S-EPMC4484697 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC3930148 | BioStudies
2015-01-01 | S-EPMC4419154 | BioStudies
1000-01-01 | S-EPMC4706127 | BioStudies
2016-05-05 | E-MTAB-3548 | ArrayExpress
2011-01-01 | S-EPMC3242525 | BioStudies
2020-01-01 | S-EPMC7583702 | BioStudies
2016-01-01 | S-EPMC5104888 | BioStudies
2019-01-01 | S-EPMC6928876 | BioStudies
1000-01-01 | S-EPMC5706421 | BioStudies
2014-01-01 | S-EPMC4371780 | BioStudies